Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

Launched by BOSTON SCIENTIFIC CORPORATION · Aug 12, 2024

Keywords

ClinConnect Summary

The RAPID for CNS study is looking at the outcomes of a treatment called radiofrequency (RF) ablation, which is used to help manage conditions like Parkinson's disease, dystonia, essential tremor, and other movement disorders. This treatment involves using heat to target specific areas in the brain to help reduce symptoms. The goal of the study is to gather real-world information about how well this treatment works for patients who are scheduled to receive it.

To participate in this study, you need to be someone who is set to receive the Boston Scientific RF ablation treatment for pain or a central nervous system condition. You will also need to provide a signed consent form, showing that you understand the study and agree to take part. However, if you have certain health issues that could affect your ability to evaluate your pain relief, or if you have cognitive impairments, you may not be eligible. If you join, you can expect to share your experiences and outcomes after your treatment, contributing valuable information to help improve care for others with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)
• • Signed a valid, IRB/EC/REB-approved informed consent form
• Exclusion Criteria:
• • Meets any contraindications per locally applicable Directions for Use (DFU)
• • Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments